Comparative Pharmacology
Head-to-head clinical analysis: AMPYRA versus DALFAMPRIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPYRA versus DALFAMPRIDINE.
AMPYRA vs DALFAMPRIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dalfampridine is a potassium channel blocker that improves conduction in demyelinated axons by prolonging action potential duration and increasing neurotransmitter release at synaptic junctions.
Potassium channel blocker that enhances neuronal transmission by prolonging repolarization and increasing neurotransmitter release in demyelinated neurons.
10 mg orally twice daily (every 12 hours). Maximum 10 mg per dose.
10 mg orally twice daily, 12 hours apart.
None Documented
None Documented
Terminal elimination half-life approximately 5-7 hours. No clinically significant accumulation with twice-daily dosing.
Clinical Note
moderateDalfampridine + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Dalfampridine."
Clinical Note
moderateDalfampridine + Ticlopidine
"The metabolism of Ticlopidine can be decreased when combined with Dalfampridine."
Clinical Note
moderateDalfampridine + Nicotine
"The metabolism of Nicotine can be decreased when combined with Dalfampridine."
Clinical Note
moderateDalfampridine + Quinidine
5-6 hours in patients with normal renal function; prolonged to 15-20 hours in moderate renal impairment.
Primarily renal elimination via glomerular filtration and active tubular secretion. ~90% of administered dose excreted unchanged in urine. Fecal/biliary excretion negligible (<1%).
Renal excretion of unchanged drug (95%); fecal (<5%).
Category C
Category C
Potassium Channel Blocker
Potassium Channel Blocker
"The serum concentration of Quinidine can be increased when it is combined with Dalfampridine."